Monday, November 23,  7:02 am

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.

Eastbourne Capital Management LLC made a plea Tuesday to Amylin Pharmaceuticals Inc. to remove potentially onerous barriers to the three-way proxy contest over the Amylin board.

Eastbourne and vehicles of Carl Icahn have independently nominated dissident slates of five directors to the 12-member, unstaggered Amylin board.

This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools.

To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button.

Dig deeper, with Pipeline.

• 1,070 articles related to Carl Icahn
• 473 company pages related to Pharmaceuticals
• 53 in-depth reports of M&A activity in the Chemicals sector
• 14 articles related to Amylin Pharmaceuticals Inc.
• 10 years of news and analysis archives from the voice of The Deal Economy
  

Most searched keywords

• Deutsche Bank
• Birds Eye
• Cadbury AG
  
• Agrium Inc.
• Skadden Arps
• Revolution Money
• Tandberg ASA
• Aisling Capital
  
• Ken Lewis
  
• Natco